These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 1490797)

  • 1. A bioequivalence study on retarded formulations of carbamazepine tablets.
    Scheuch E; Hoffmann C; Franke G; Rabending G; Zschiesche M; Siegmund W
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):486-7. PubMed ID: 1490797
    [No Abstract]   [Full Text] [Related]  

  • 2. A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine.
    Yacobi A; Zlotnick S; Colaizzi JL; Moros D; Masson E; Abolfathi Z; LeBel M; Mehta R; Golander Y; Levitt B
    Clin Pharmacol Ther; 1999 Apr; 65(4):389-94. PubMed ID: 10223775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets.
    Ikinci G; Capan Y; Senel S; Dalkara T; Hincal AA
    Pharmazie; 1999 Feb; 54(2):139-41. PubMed ID: 10084159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration.
    Wangemann M; Retzow A; Evers G; Mazur D; Schug B; Blume H
    Arzneimittelforschung; 1998 Dec; 48(12):1131-7. PubMed ID: 9893926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market.
    Oluka MO; Mitema ES; Kibwage IO; Kwasa TO; Kokwaro GO
    East Afr Med J; 1996 May; 73(5):323-6. PubMed ID: 8756037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
    Miller AD; Krauss GL; Hamzeh FM
    Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic comparison of two carbamazepine slow-release formulations.
    Jensen PK; Møller A; Gram L; Jensen NO; Dam M
    Acta Neurol Scand; 1990 Aug; 82(2):135-7. PubMed ID: 2256443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are immediate- and extended-release drugs interchangeable?
    Cohen D; Loonen AJ
    Acta Psychiatr Scand; 2013 Jan; 127(1):78-80. PubMed ID: 23121193
    [No Abstract]   [Full Text] [Related]  

  • 11. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations.
    Wolf P; May T; Tiska G; Schreiber G
    Arzneimittelforschung; 1992 Mar; 42(3):284-8. PubMed ID: 1497685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of food on the bioavailability of a carbamazepine slow-release formulation.
    Retzow A; Schürer M; Schulz HU
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):557-60. PubMed ID: 9455713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The bioequivalence of two nifedipine sustained-release formulations after single administration in steady state].
    Meyer FP; Banditt P
    Arzneimittelforschung; 1993 Jun; 43(6):646-50. PubMed ID: 8352817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation.
    Nag D; Garg RK; Agarwal A
    J Assoc Physicians India; 1998 Feb; 46(2):185-8. PubMed ID: 11273108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence study of generic atenolol tablets in healthy Thai volunteers.
    Rojanasthien N; Manorot M; Kumsorn B
    J Med Assoc Thai; 1999 Sep; 82(9):907-14. PubMed ID: 10561948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and central side effects of different carbamazepine tablets.
    Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):226-32. PubMed ID: 3997307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of a slow-release potassium tablet and a liquid potassium supplement.
    Lowance DC; Murad F; Darrow WR; Bonus L
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):204-8. PubMed ID: 7095919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bioavailability with two brands of carbamazepine-Tegretol and Mazetol in healthy volunteers.
    Bhatia SC; Bhatt AD; Bakshi RJ; Revankar SN; Bharucha ED; Doshi KJ; Nagarsenkar SS; Shah NN; Marthak KV; Bolar HV
    J Assoc Physicians India; 1988 Oct; 36(10):611-2. PubMed ID: 3220811
    [No Abstract]   [Full Text] [Related]  

  • 20. HPLC analysis of theophylline: bioequivalence study of two sustained-release formulations at steady state.
    Mazzei M; Sottofattori E; Balbi A; Bottino GB
    Farmaco; 1992 May; 47(5 Suppl):769-77. PubMed ID: 1524625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.